Business Context and Reporting Period
This Form 6-K filing by Genmab A/S covers the month of January 2026, with the report dated January 29, 2026. The filing serves as a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance and compensation rather than a financial results statement.
Material Changes
The primary material event disclosed in this filing is the grant of Restricted Stock Units (RSUs) and Warrants to employees, as detailed in the attached Company Announcement (Exhibit 99.1). No other material changes to financial position or operations are described in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document focuses solely on the execution of the employee equity grant.
Key Facts for Investor Verification
- Verify the specific terms, vesting schedules, and number of RSUs and Warrants granted to employees in the attached Exhibit 99.1.
- Confirm the impact of this grant on the company's share count and potential dilution.
- Note that this filing incorporates by reference into Genmab's registration statements on Form S-8.